Products for Research Use Only

SEN177

CAT: 0804-HY-136780-01Size: 5 mgDry Ice: NoHazardous: No
Product image 1
1 / 1
CAT#:0804-HY-136780-01Size:5 mg
Selected
24/48H Stock Items & 2 to 6 Weeks non Stock Items.
Quick Request Actions
Description
SEN177 is an orally effect glutamine cyclase (QC) inhibitor. The Ki of SEN177 for human glutamine cyclase (hQC) is 20 nM, and the IC50 is 13 nM. SEN177 interferes with the interaction between CD47 and SIRRPα, and has anti-tumor activity. SEN177 reduces aggregation and apoptosis caused by HTT mutation in Huntington model, and can be used in the study of neurodegenerative diseases[1][2][3].
CAS Number
2117405-13-5
UNSPSC
12352005
Hazard Statement
H301
Target
Amyloid-β; Apoptosis; CD47; Huntingtin
Type
Reference compound
Related Pathways
Apoptosis; Immunology/Inflammation; Neuronal Signaling
Applications
Neuroscience-Neurodegeneration
Field of Research
Cancer; Neurological Disease
Assay Protocol
https://www.medchemexpress.com/sen177.html
Purity
98.76
Solubility
DMSO : 31.25 mg/mL (ultrasonic)
Smiles
CN1C(C2CCN(C3=NC=CC=C3C4=CC=C(F)N=C4)CC2)=NN=C1
Molecular Formula
C18H19FN6
Molecular Weight
338.38
Precautions
H301
References & Citations
[1]Cecilia Pozzi, et al. The structure of the human glutaminyl cyclase-SEN177 complex indicates routes for developing new potent inhibitors as possible agents for the treatment of neurological disorders. J Biol Inorg Chem. 2018 Dec;23 (8) :1219-1226.|[2]Maria Jimenez-Sanchez, et al. siRNA screen identifies QPCT as a druggable target for Huntington's disease. Nat Chem Biol. 2015 May;11 (5) :347-354.|[3]Baumann N, et al. Enhancement of epidermal growth factor receptor antibody tumor immunotherapy by glutaminyl cyclase inhibition to interfere with CD47/signal regulatory protein alpha interactions. Cancer Sci. 2021 Aug;112 (8) :3029-3040.
Shipping Conditions
Blue Ice
Storage Conditions
-20°C, 3 years (Powder)
Scientific Category
Reference compound1
Clinical Information
No Development Reported

Alternative Products

CatalogName
BA8412-5SEN177